Methicillin resistant Staphylococcus aureus;Resistencia del Staphylococcus a la meticilina

Medicina

Volumn 62, Issue SUPPL. 2, 2002, Pages 30-35

  Marin, Marcelo ^a  

^a Fundacion Centro de Estudios Infectologicos   (Argentina)

Author keywords

Glycopeptides; Methicillin; Resistance; Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; METICILLIN; MINOCYCLINE; OXACILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY; FRANCE; GENETIC CODE; HOSPITAL INFECTION; HUMAN; JAPAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; NONHUMAN; PATHOGENICITY; PENICILLIN RESISTANCE; PHYSICIAN; PREVALENCE; PROTEIN ISOLATION; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0036449020     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Weinstein MP, Towns ML, Quartey SM et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
2. Cockerill FR 3rd, Hughes JG, Vetter EA et al. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. Clin Infect Dis 1997; 24: 403-18.
3. Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrob Agents 2000; 16: S3-10.
4. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002; 15: 430-8.
5. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
6. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
7. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 765-6.
8. Benner EJ, Kayser FH. Growing clinical significance of methcillin-resistant Staphylococcus aureus. Lancet 1968; 2: 741-4.
9. Stewart GT, Holt RJ. Evolution of natural resistance to the newer penicillin. Br Med J 1963; 1: 308-11.
10. Chambers H F. Methicillin Resistance in Staphylococci: Molecular and Biochemical Basis and Clinical Implications. Clin Microbiol Rev 1997; 10: 781-91.
11. de Lencastre H, de Jonge BL, Matthews PR, Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 7-24.
12. Tomasz A, Drugeon HB, de Lencastre HM, Jabes D, McDougall L, Bille J. New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity. Antimicrob Agents Chemother 1989; 33: 1869-74.
13. Berger-Bachi B, Strassle A, Kayser FH. Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. Eur J Clin Microbiol 1986; 5: 697-70.
14. Henze UU, Berger-Bachi B. Penicillin-binding protein 4 overproduction increases beta-lactam. Antimicrob Agents Chemother 1996; 40: 2121-5.
15. Kernodle DS, Stratton CW, McMurray LW, Chipley JR, McGraw PA. Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles. J Infect Dis 1989; 159: 103-8.
16. Massidda O, Montanari MP, Varaldo PE. Evidence for a methicillin-hydrolysing beta-lactamase in Staphylococcus aureus strains with borderline susceptibility to this drug. Fems Microbiol Lett 1992; 92: 223-7.
17. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. National Committee for Laboratory Standards Wayne, Pa; 2000, Document M100-S9.
18. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. National Committee for Laboratory Standards Wayne, Pa; 2000, Document M100-S10.
19. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. National Committee for Laboratory Standards Wayne, Pa; 2002, M100-S12.
20. Gradelski E, Valera L, Aleksunes L, Bonner D, FungTomc J. Correlation between genotype and phenotypic categorization of staphylococci based on methicillin susceptibility and resistance. J Clin Microbiol 2001; 39: 2961-3.
21. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: A 10-year study. JAMA 1993; 269: 598-602.
22. Geraci JE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. In: Antibiotic annual 1955-1956. New York: Medical Encyclopedia. 1956, p. 90-106.
23. Ziegler DW. Vancomycin a new antibiotic II. In vitro antibacterial studies. In: Antibiotic annual 1955-1956. New York: Medical Encyclopedia, 1956, p. 612-6.
24. Subcomisión de Antimicrobianos, SADEBAC, AAM y Grupo SIR. Sistema Informático de Resistencia (SIR). Análisis de Prevalencia del Año 2000. Asociación Argentina de Microbiología 2002; Boletín N° 153.
25. Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181: 7566-70.
26. Daum RS, Gupta S, Sabbagh R, Milewski WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 1992;166: 1066-72.
27. VRSA, VISA, and GISA: The Dilemma Behind the Name Game - Reduced susceptibility of Staphylococcus aureus isolates to vancomycin has resulted in the use of a variety of different acronyms. The differences in the terms and the uncertainty over their significance are reviewed and discussed. Clin Microbiol News 2000; 22: 49-52.
28. Cox RA, Mallaghan C, Conquest C, King J. Epidemic methicillin-resistant Staphylococcus aureus: controlling the spread outside hospital. J Hosp Infect 1995; 29: 107-19.
29. Crisp C, Patterson JE, Moreno F, Jorgensen JH. Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995; 21: 1308-12.
30. Soloaga R, Procopio A, Aguilar J et al. Comparison of different detection methods for methicillin resistance in Staphylococcus aureus. Rev Argent Microbiol 2002; 34: 52-6.
31. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46: 626-8, 635.